| Literature DB >> 35115045 |
Duku Chaplain1, Butti Ben Asutaku1, Muhammad Mona1, Douglas Bulafu2, Dickson Aruhomukama3,4.
Abstract
BACKGROUND: Lab-based surveillance (LBS) of antimicrobial resistance (AMR) is not systematically implemented in Uganda. We aimed to identify the gaps in establishing regular LBS of AMR in Uganda.Entities:
Keywords: Antimicrobial resistance; Microbiology labs; Mulago Hospital; Surveillance; Uganda
Mesh:
Substances:
Year: 2022 PMID: 35115045 PMCID: PMC8812180 DOI: 10.1186/s13756-022-01072-4
Source DB: PubMed Journal: Antimicrob Resist Infect Control ISSN: 2047-2994 Impact factor: 4.887
Bacteria isolated from the samples
| Isolated bacteria (N = 478) | |||
|---|---|---|---|
| Gram-negative bacteria | f (%) | Gram-positive bacteria | f (%) |
| 100 (37) | 20 (10) | ||
| 64 (24) | 176 (83) | ||
| 13 (5) | 4 (2) | ||
| 1 (0.4) | 3 (1) | ||
| 1 (0.4) | 2 (1) | ||
| 26 (10) | 6 (3) | ||
| 1 (0.4) | |||
| + | 17 (6) | ||
| *Others | 44 (16) | ||
*Others-UGNB, #Enterobacteriaceae, +non-Enterobacteriaceae, **Coagulase negative staphylococcus
Antimicrobial susceptibility profiles of the most common gram-positive bacteria
| Antimicrobials | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| R | S | R | S | R | S | R | S | R | S | |
| AMP | 46 (86.8) | 7 (13.2) | 1 (50) | 1 (50) | 1 (100) | 0 (0) | 3 (50) | 3 (50) | 1 (100) | 0 (0) |
| A | 1 (100) | 0 (0) | c | c | a | a | c | c | a | a |
| FOX | 17 (32.7) | 33 (63.5) | c | c | c | c | c | c | c | c |
| SXT | 39 (66.1) | 19 (32.2) | 1 (100) | 0 (0) | c | c | c | c | c | c |
| CIP | 21 (52.5) | 18 (45) | c | c | c | c | 2 (100) | 0 (0) | c | c |
| CN | 51 (52.6) | 46 (46.9) | c | c | c | c | c | c | 1 (100) | 0 (0) |
| P | a | a | a | a | a | a | a | a | a | a |
| VAN | 13 (13.7) | 82 (86.3) | 0 (0) | 1 (100) | 0 (0) | 1 (100) | 1 (33.3) | 2 (66.7) | 0 (0) | 1 (100) |
| AMC | c | c | 1 (50) | 1 (50) | c | c | c | c | c | c |
| C | 28 (42.4) | 38 (57.6) | 1 (100) | 0 (0) | a | a | a | a | a | a |
| DA | 9 (19.1) | 38 (80.9) | a | a | a | a | c | c | a | a |
| E | c | c | a | a | 1 (100) | 0 (0) | 1 (50) | 1 (50) | 1 (100) | 0 (0) |
| N | 1 (16.7) | 5 (83.3) | c | c | c | c | 1 (100) | 0 (0) | c | c |
| CTX | c | c | a | a | a | a | c | c | a | a |
| IMP | c | c | a | a | a | a | c | c | a | a |
| CRO | c | c | a | a | a | a | c | c | a | a |
| TE | 12 (80) | 2 (13.3) | a | a | a | a | 0 (0) | 3 (100) | a | a |
| CXM | c | c | a | a | a | a | c | c | c | c |
| RIF | 3 (16.7) | 15 (83.3) | 0 (0) | 1 (100) | c | c | 1 (50) | 1 (50) | c | c |
| AZT | c | c | c | c | c | c | c | c | c | c |
R—Resistant, S—Sensitive, %—bacteria screened against a particular antimicrobial, a and c—antimicrobial not screened against the bacteria (due to c—CLSI guidelines or a—total absence or unavailability in the lab), AMP—Ampicillin, A—Azithromycin, FOX—Cefoxitin, CN—Gentamicin, IPM—Imipenem, CIP—Ciprofloxacin, CTX—Cefotaxime, AZT—Aztreonam, AMC—Amoxicillin-clavulanic acid, N—Nitrofurantoin, SXT—Cotrimoxazole, CXM—Cefuroxime, CRO—Ceftriaxone, C—Chloramphenicol, P—Penicillin, VAN—Vancomycin, DA—Clindamycin, E—Erythromycin, TE—Tetracycline, RIF—Rifampicin
Antimicrobial susceptibility profiles of the most common gram-negative bacteria
| Antimicrobials | UGNB | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| R | S | R | S | R | S | R | S | R | S | |
| CN | 32 (48.5) | 33 (50) | 10 (66.7) | 4 (26.6) | 16 (80) | 4 (20) | 1 (10) | 8 (80) | 7 (77.8) | 1 (11.1) |
| IMP | 0 (0) | 77 (100) | 0 (0) | 20 (100) | 2 (50) | 2 (50) | 1 (7.7) | 12 (92.3) | 1 (6.7) | 14 (93.3) |
| CAZ | 38 (65.5) | 1 (29.3) | 8 (100) | 0 (0) | 14 (82.4) | 2 (11.7) | 1 (10) | 9 (90) | 4 (44.4) | 3 (33.3) |
| CIP | 28 (74.5) | 8 (21.6) | 7 (58.3) | 4 (33.4) | 9 (64.3) | 4 (28.6) | 0 (0) | 6 (100) | 7 (53.8) | 6 (46.2) |
| CTX | 13 (86.7) | 2 (13.3) | 1 (100) | 0 (0) | 1 (100) | 0 (0) | c | c | 6 (100) | 0 (0) |
| AMP | 26 (96.3) | 1 (3.7) | 5 (100) | 0 (0) | 8 (100) | 0 (0) | c | c | 14 (100) | 0 (0) |
| AZT | 2 (100) | 0 (0) | a | a | 2 (100) | 0 (0) | 1 (100) | 0 (0) | 1 (100) | 0 (0) |
| AMC | 18 (27.7) | 43 (66.1) | 3 (25) | 9 (75) | 10 (37.1) | 15 (55.5) | c | c | 4 (33.3) | 8 (66.7) |
| N | 5 (10.4) | 4 (85.4) | 0 (0) | 3 (100) | 4 (50) | 4 (50) | c | c | 0 (0) | 3 (75) |
| SXT | 32 (91.4) | 3 (8.6) | 7 (87.5) | 1 (12.5) | 10 (90.9) | 1 (9.1) | c | c | 0 (0) | 0 (0) |
| CXM | 2 (100) | 0 (0) | a | a | 6 (100) | 0 (0) | c | c | 2 (50) | 2 (50) |
| NA | 13 (59.1) | 7 (31.8) | 1 (100) | 0 (0) | 5 (71.4) | 2 (28.6) | c | c | 3 (100) | 0 (0) |
| CRO | 2 (69) | 8 (27.6) | 7 (75) | 3 (25) | 6 (100) | 0 (0) | c | c | 3 (60) | 2 (40) |
| C | 9 (36) | 16 (64) | 5 (50) | 5 (50) | 9 (56.3) | 7 (43.7) | c | c | 1 (100) | 0 (0) |
| AK | 0 (0) | 2 (66.7) | a | a | a | a | a | a | 1 (100) | 0 (0) |
| FOX | 5 (83.3) | 1 (16.7) | 1 (33.3) | 2 (66.7) | 5 (62.5) | 3 (37.5) | c | c | a | a |
| MEM | 0 (0) | 3 (100) | a | a | 0 (0) | 1 (100) | a | a | a | a |
| TPZ | a | a | a | a | a | a | 0 (0) | 3 (100) | a | a |
R—Resistant, S—Sensitive, %—bacteria screened against a particular antimicrobial, a and c—antimicrobial not screened against the bacteria (due to c—CLSI guidelines or a—total absence or unavailability in the lab), CN—Gentamicin, IPM—Imipenem, CAZ—Ceftazidime, CIP—Ciprofloxacin, CTX—Cefotaxime, AMP—Ampicillin, AZT—Aztreonam, AMC—Amoxicillin-clavulanic acid, N—Nitrofurantoin, SXT—Cotrimoxazole, CXM—Cefuroxime, NA—Nalidixic acid, CRO—Ceftriaxone, C—Chloramphenicol, AK—Amikacin, MEM—Meropenem, FOX—Cefoxitin, MEM—Meropenem, TPZ—Tazobactam piperacillin